Clinical Trials
22 trialsNCT07021989 2026-06-04
ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma
University of California, San Francisco
Phase 2 Not yet recruiting
NCT06377566 2026-04-23
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT03618550 2026-04-16
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05300282 2026-01-28
FIL_A-BEGEV
Fondazione Italiana Linfomi - ETS
Phase 1/2 Recruiting
NCT00574496 2023-09-28
Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01026220 2022-04-28
Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma
Children's Oncology Group
Phase 3 Completed
NCT00302003 2021-03-30
Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma
Children's Oncology Group
Phase 3 Completed
NCT00381940 2021-03-24
Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00388349 2017-06-14
Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease
Stanford University
Phase 2 Completed
NCT00881387 2016-12-15
Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatment
University of Miami
Phase 2 Withdrawn
NCT00920153 2016-09-16
Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma
French Innovative Leukemia Organisation
Phase 3 Terminated
NCT00006029 2016-07-14
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
Alliance for Clinical Trials in Oncology
Phase 1/2 Completed
NCT00163748 2016-01-08
Efficacy and Treatment Related Toxicity Study of a New Regimen for Lymphoma
Bayside Health
Phase 2 Completed
NCT00163761 2016-01-08
Efficacy Study of Outpatient Therapy for Lymphoma
Bayside Health
Phase 2 Completed
NCT00337194 2015-02-23
SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00225173 2014-08-27
Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease
Stanford University
Phase 2 Terminated
NCT01884428 2014-01-29
Study of Combination of PIGEV Before Autologous Stem Cell Transplant in Patients With Hodgkin's Lymphoma
Istituto Clinico Humanitas
Phase 1 Unknown
NCT01884441 2014-01-29
Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients
Istituto Clinico Humanitas
Phase 2 Unknown
NCT00006760 2013-07-26
Combination Chemotherapy in Treating Children With Refractory or Relapsed Hodgkin's Lymphoma
Children's Oncology Group
Phase 2 Completed
NCT00070304 2013-07-26
Gemcitabine and Vinorelbine in Treating Young Patients With Recurrent or Refractory Hodgkin's Lymphoma
Children's Oncology Group
Phase 2 Completed
NCT00004105 2011-03-28
Combination Chemotherapy in Treating Patients With Advanced Cancer
NYU Langone Health
Phase 1/2 Completed
NCT00636311 2010-09-02
A Phase II Study of IGEV +/- Bortezomib Before Hign Dose Consolidation in Relapsed/Refractory Hodgkin's Lymphoma
Istituto Clinico Humanitas
Phase 2 Completed